Skip to Content

Viking Therapeutics Inc VKTX

Morningstar Rating
$67.00 −2.06 (2.98%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

VKTX is trading within a range we consider fairly valued.
Price
$66.92
Fair Value
$859.52
Uncertainty
Extreme
1-Star Price
$684.22
5-Star Price
$98.80
Economic Moat
Jfgcp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VKTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$69.06
Day Range
$66.6871.09
52-Week Range
$8.2899.41
Bid/Ask
$67.10 / $67.29
Market Cap
$7.39 Bil
Volume/Avg
4.1 Mil / 6.3 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
27

Comparables

Valuation

Metric
VKTX
CBAY
EWTX
Price/Earnings (Normalized)
Price/Book Value
7.9112.653.16
Price/Sales
111.01
Price/Cash Flow
Price/Earnings
VKTX
CBAY
EWTX

Financial Strength

Metric
VKTX
CBAY
EWTX
Quick Ratio
29.3810.7036.49
Current Ratio
29.4810.9637.08
Interest Coverage
−5.27
Quick Ratio
VKTX
CBAY
EWTX

Profitability

Metric
VKTX
CBAY
EWTX
Return on Assets (Normalized)
−15.98%−30.06%−23.18%
Return on Equity (Normalized)
−16.71%−51.97%−24.45%
Return on Invested Capital (Normalized)
−21.42%−30.87%−28.92%
Return on Assets
VKTX
CBAY
EWTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRkwvctrcbxChlz$586.1 Bil
VRTX
Vertex Pharmaceuticals IncVvwphrhTwncw$113.7 Bil
REGN
Regeneron Pharmaceuticals IncTttwnjcwmLsvfvs$108.2 Bil
MRNA
Moderna IncJhxzfvdHqtzm$50.9 Bil
ARGX
argenx SE ADRZnjvxwvRdsk$22.0 Bil
BNTX
BioNTech SE ADRSwbnrsfjPpr$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncKllnqmcTfsngys$18.9 Bil
BMRN
Biomarin Pharmaceutical IncWjbxdlnrLybygz$14.6 Bil
INCY
Incyte CorpYdndybxqQkqpkk$12.8 Bil
RPRX
Royalty Pharma PLC Class AYwbpxzttMcvxkr$12.3 Bil

Sponsor Center